Nitroxoline treatment significantly reduced liver weight in high-fat diet-fed mice without affecting body weight.
Serum levels of total cholesterol, low-density lipoprotein (LDL)-cholesterol, and triglycerides were markedly decreased with Nit treatment.
Nit enhanced the expression of transporters ABCG5 and ABCG8, and cholesterol 7α-hydroxylase (CYP7A1), promoting cholesterol efflux into bile.
In Huh-7 cells, Nit induced ABCG5, ABCG8, and CYP7A1 expression in a dose-dependent manner.
RNA sequencing identified liver receptor homolog-1 () as a potential regulator of Nit's effects.
Inhibition of LRH-1 abolished the upregulation of ABCG5, ABCG8, and CYP7A1, suggesting Nit may alleviate lipid accumulation through LRH-1 activation.
Simplified
BACKGROUND: Metabolic associated fatty liver disease () has emerged as the most common chronic liver disease worldwide. However, effective pharmacological treatments remain limited. Dysregulated lipid metabolism and impaired bile acid synthesis are recognized as key contributors to the pathogenesis of MAFLD. This study aimed to investigate the therapeutic potential and underlying mechanisms of nitroxoline (Nit), an antimicrobial agent identified through drug repurposing, in ameliorating hepatic steatosis.
METHODS: Nit was administered to high-fat diet (HFD)-fed low-density lipoprotein receptor knockout (Ldlr) mice to assess hepatic steatosis, aortic atherosclerosis, serum lipid levels, and bile acid metabolism comprehensively. In vitro, Huh-7 cells were used to examine Nit-mediated regulation of lipid metabolism-related genes. RNA sequencing (RNA-seq) and pharmacologic inhibition studies were conducted to elucidate the underlying molecular mechanisms. ⁻/⁻
RESULTS: Nit treatment significantly reduced liver weight without affecting body weight in HFD-fed Ldlr⁻/⁻ mice. Serum total cholesterol, low-density lipoprotein (LDL)-cholesterol, and triglyceride levels were markedly decreased. Mechanistically, Nit enhanced the expression of ATP-binding cassette subfamily G5 (ABCG5) and G8 (ABCG8) transporters, along with cholesterol 7α-hydroxylase (CYP7A1), thereby promoting cholesterol efflux into bile and bile acid synthesis. In Huh-7 cells, Nit induced ABCG5, ABCG8 and CYP7A1 expression in a dose-dependent manner. Furthermore, RNA-Seq analysis revealed liver receptor homolog-1 () as a potential transcriptional regulator related to Nit. Notably, pretreatment with the LRH-1 inhibitor, ML-180 abolished Nit-induced upregulation of ABCG5, ABCG8 and CYP7A1, suggesting that Nit may alleviate hepatic lipid accumulation primarily through LRH-1 activation.
CONCLUSIONS: This study identifies Nit as a promising pharmacological candidate for MAFLD by modulating cholesterol metabolism and bile acid synthesis through LRH-1-mediated activation. These findings not only advance the understanding of metabolic liver disease pathogenesis but also support the development of innovative and accessible therapeutic strategies by leveraging existing compounds to improve health outcomes.
Key numbers
Markedly decreased
Decrease in Serum Total Cholesterol
Measured in high-fat diet-fed mice treated with Nit
Not specified
Reduction in Liver Weight
Observed in high-fat diet-fed mice treated with Nit
Full Text
We can’t show the full text here under this license.
Declarations. Ethics approval and consent to participate: All animal experiments in this study were approved by the Ethics and Animal Welfare Committee, National Defense Medical Center, Taipei, Taiwan (IACUC-23–020). The study complied with the relevant ethical regulations pertaining to animal research, and all laboratory animals were cared for and used according to institutional guidelines. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.
